224 related articles for article (PubMed ID: 17538173)
41. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
42. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
43. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
Lee DP; Skolnik JM; Adamson PC
J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
[TBL] [Abstract][Full Text] [Related]
44. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
45. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
46. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
Passardi A; Maltoni R; Milandri C; Cecconetto L; Massa I; Zoli W; Tesei A; Fabbri F; Nanni O; Amadori D
Oncology; 2007; 72(1-2):118-24. PubMed ID: 18004083
[TBL] [Abstract][Full Text] [Related]
47. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report.
Gaynon PS; Ettinger LJ; Moel D; Siegel SE; Baum ES; Krivit W; Hammond GD
Cancer Treat Rep; 1987 Nov; 71(11):1039-42. PubMed ID: 3315195
[TBL] [Abstract][Full Text] [Related]
48. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
[TBL] [Abstract][Full Text] [Related]
49. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Bagatell R; Gore L; Egorin MJ; Ho R; Heller G; Boucher N; Zuhowski EG; Whitlock JA; Hunger SP; Narendran A; Katzenstein HM; Arceci RJ; Boklan J; Herzog CE; Whitesell L; Ivy SP; Trippett TM
Clin Cancer Res; 2007 Mar; 13(6):1783-8. PubMed ID: 17363533
[TBL] [Abstract][Full Text] [Related]
50. A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP).
Mathé G; Kidani Y; Triana K; Brienza S; Ribaud P; Goldschmidt E; Ecstein E; Despax R; Musset M; Misset JL
Biomed Pharmacother; 1986; 40(10):372-6. PubMed ID: 3580505
[TBL] [Abstract][Full Text] [Related]
51. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
52. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
Taieb S; Trillet-Lenoir V; Rambaud L; Descos L; Freyer G
Cancer; 2002 May; 94(9):2434-40. PubMed ID: 12015768
[TBL] [Abstract][Full Text] [Related]
53. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
Beerepoot LV; Radema SA; Witteveen EO; Thomas T; Wheeler C; Kempin S; Voest EE
J Clin Oncol; 2006 Apr; 24(10):1491-8. PubMed ID: 16574998
[TBL] [Abstract][Full Text] [Related]
54. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
[TBL] [Abstract][Full Text] [Related]
55. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.
McGregor LM; Spunt SL; Santana VM; Stewart CF; Ward DA; Watkins A; Laningham FH; Ivy P; Furman WL; Fouladi M
Cancer; 2009 Feb; 115(3):655-64. PubMed ID: 19117350
[TBL] [Abstract][Full Text] [Related]
56. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
57. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Lee JL; Kang HJ; Kang YK; Ryu MH; Chang HM; Kim TW; Sohn HJ; Kim H; Lee JS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):837-45. PubMed ID: 17579864
[TBL] [Abstract][Full Text] [Related]
58. Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
Winograd B; Vermorken JB; ten Bokkel Huinink WW; Simonetti G; Gall HE; Knobf MK; van der Vijgh WJ; McVie JG; Pinedo HM
Cancer Res; 1986 Apr; 46(4 Pt 2):2148-51. PubMed ID: 3948186
[TBL] [Abstract][Full Text] [Related]
59. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Shibata S; Chow W; Frankel P; Juhasz A; Leong L; Lim D; Margolin K; Morgan R; Newman E; Somlo G; Yen Y; Synold T; Gandara D; Lenz HJ; Doroshow J
Cancer Chemother Pharmacol; 2007 Mar; 59(4):549-57. PubMed ID: 17051371
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
